Clinical Development Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Clinical Development stocks.

Clinical Development Stocks Recent News

Date Stock Title
Nov 23 BBIO Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Nov 22 MCRB Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Nov 22 CYTK Cytokinetics price target raised to $103 from $99 at Mizuho
Nov 21 BBIO Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
Nov 21 CYTK Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?
Nov 21 NVAX Matt Gaetz Withdraws. Why That Might Be Bad News for RFK.
Nov 20 NVAX Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)
Nov 20 CYTK Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Nov 19 CYTK Cytokinetics and Bayer partner to develop for aficamten in Japan
Nov 19 NXTC Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
Nov 19 CYTK Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
Nov 19 CYTK Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan
Nov 19 CYTK Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Nov 19 CYTK Bayer acquires rights to Cytokinetics' heart drug in Japan
Nov 19 CYTK Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Nov 18 NKTR Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Clinical Development

Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

Browse All Tags